BeiGene Ltd.
- Country
- 🇨🇳China
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $22.1B
- Website
- http://www.beigene.com
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
- Conditions
- Chronic Lymphocytic LeukemiaCLL
- Interventions
- First Posted Date
- 2024-11-20
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 56
- Registration Number
- NCT06697184
- Locations
- 🇫🇷
Hopital Larchet Chu Nice, Nice, France
🇫🇷Iuct Oncopole, Toulouse, France
🇫🇷Hopital Avicenne, Aphp, Bobigny, Bobigny, France
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
- Conditions
- Non-Small Cell Lung CancerLung CancerNSCLCNSCLC (Non-small Cell Lung Carcinoma)EGFR Activating MutationEGFR Mutation-Related Tumors
- Interventions
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 93
- Registration Number
- NCT06685718
- Locations
- 🇰🇷
Chungbuk National University Hospital, SeowonGu CheongjuSi, Chungcheongbukdo, Korea, Republic of
🇰🇷Samsung Medical Center, GangnamGu, Seoul Teugbyeolsi, Korea, Republic of
🇰🇷Severance Hospital Yonsei University Health System, SeodaemunGu, Seoul Teugbyeolsi, Korea, Republic of
A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 87
- Registration Number
- NCT06637501
- Locations
- 🇵🇱
Pratia McM Krakow, Krakow, Poland
🇵🇱Pratia Onkologia Katowice, Katowice, Poland
🇺🇸University of Miami, Miami, Florida, United States
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
- Conditions
- B-cell MalignancyRelapsed CancerRefractory CancerB-cell Lymphoma
- Interventions
- First Posted Date
- 2024-10-10
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 80
- Registration Number
- NCT06634589
- Locations
- 🇮🇹
Centroricerche Cliniche Di Verona Srl, Verona, Italy
🇺🇸Mayo Clinic Phoenix, Phoenix, Arizona, United States
🇺🇸University of Southern Californianorris Comprehensive, Los Angeles, California, United States
A First-in-Human Study of BG-C137, an Anti-FGFR2b Antibody Drug Conjugate, in Participants With Advanced Solid Tumors
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 68
- Registration Number
- NCT06625593
- Locations
- 🇰🇷
Samsung Medical Center, GangnamGu, Seoul Teugbyeolsi, Korea, Republic of
🇰🇷Asan Medical Center, SongpaGu, Seoul Teugbyeolsi, Korea, Republic of
🇺🇸Usc Norris Comprehensive Cancer Center (Nccc), Los Angeles, California, United States
An Investigational Study of BGB-58067 in Participants With Advanced Solid Tumors
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 92
- Registration Number
- NCT06589596
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳The Second Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumor
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 87
- Registration Number
- NCT06598800
- Locations
- 🇨🇳
Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China
🇨🇳Chongqing University Cancer Hospital, Chongqing, Chongqing, China
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
A Study of BG-C477 in Participants With Advanced Solid Tumors
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 21
- Registration Number
- NCT06596473
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸Yale University, Yale Cancer Center, New Haven, Connecticut, United States
🇨🇳Sun Yat Sen University Cancer Center, Guangzhou, Guangdong, China
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
- Conditions
- Metastatic Solid TumorsAdvanced Non-squamous Non-small-cell Lung CancerAdvanced Colorectal CancerAdvanced Pancreatic Ductal AdenocarcinomaAdvanced Gastric CancerAdvanced Gastroesophageal Junction CancerAdvanced Esophageal Adenocarcinoma
- Interventions
- First Posted Date
- 2024-09-05
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 177
- Registration Number
- NCT06585488
- Locations
- 🇺🇸
Usc Norris Comprehensive Cancer Center (Nccc), Los Angeles, California, United States
🇺🇸University of Kansas Medical Center Research Institute, Kansas City, Kansas, United States
🇺🇸Sidney Kimmel Comprehensive Cancer At Johns Hopkins, Baltimore, Maryland, United States
A Study to Evaluate the Effects of Phenytoin and Itraconazole on Sonrotoclax (BGB-11417) in Healthy Volunteers
- Conditions
- Not Determined
- Interventions
- First Posted Date
- 2024-08-07
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 30
- Registration Number
- NCT06543043
- Locations
- 🇺🇸
Quotient Sciences, Miami, Florida, United States